Clinical Trials
11 trialsNCT00098423 2013-09-30
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed
NCT00100997 2013-07-10
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
National Cancer Institute (NCI)
Phase 1 Completed
NCT00004065 2013-06-24
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00079404 2013-06-05
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00093821 2013-06-04
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00066326 2013-04-05
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT00303797 2013-03-19
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00004241 2013-02-07
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00132015 2012-03-15
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00004075 2011-08-03
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Mayo Clinic
Phase 1 Completed
NCT00113204 2008-05-20
IPi-504-01
Infinity Pharmaceuticals, Inc.
Phase 1 Completed